Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Brii Biosciences Limited ( (HK:2137) ) is now available.
Brii Biosciences has presented new data at the Asian Pacific Association for the Study of the Liver meeting in Istanbul, detailing a cross-study analysis of post-treatment hepatitis B surface antigen rebound in NRTI-experienced patients from its Phase 2 ENSURE and BRII-179-002 trials. The pooled analysis assessed the incidence, magnitude and clinical significance of HBsAg rebound after end of treatment in patients receiving pegylated interferon alfa alone or in combination with elebsiran or BRII-179.
The findings indicate that off-treatment clinical outcomes were favorable, with all HBsAg rebounds remaining below 100 IU/mL and most below 10 IU/mL, while HBV DNA rebound was rare and not associated with significant ALT elevations. These results suggest durable post-treatment immunological control, support the potential for safely discontinuing NRTIs in pegylated interferon-based combination regimens, and imply that shorter or even eliminated NRTI consolidation periods could be feasible in future HBV cure strategies, reinforcing the strategic value of BRII-179 and elebsiran in the company’s pipeline.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing novel therapies for infectious diseases, with a particular emphasis on chronic hepatitis B virus (HBV) infection. Its pipeline includes candidates such as BRII-179 and elebsiran, which are being evaluated in combination with established treatments like pegylated interferon alfa to improve functional cure rates.
YTD Price Performance: 0.71%
Average Trading Volume: 1,225,754
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.02B
For detailed information about 2137 stock, go to TipRanks’ Stock Analysis page.